A study to evaluate the safety of REGN7041 in adults with active noninfectious uveitis affecting the back of the eye.

1 1

What is this study about?

This study focuses on individuals living with Noninfectious Uveitis affecting the posterior segment, which refers to the back part of the eye. This condition involves inflammation in the eye that is not caused by an infection. The investigation aims to evaluate the safety and how well the body tolerates the study drug.

The treatment being tested is an anti-CD3 monoclonal antibody called REGN7041. This medication is provided as a solution for injection and is administered via intravitreal use, which means the medicine is injected directly into the jelly-like substance inside the eye. Participants may receive either a single dose or repeated doses of this substance during the course of the study.

Who Can Join the Study?

You must have a diagnosis of non-infectious uveitis, which is a type of inflammation inside the eye that is not caused by an infection like a virus or bacteria.
The inflammation must be present in different parts of the eye, such as the anterior (front), intermediate (middle), posterior (back), or panuveitis (affecting all parts of the eye).
If the inflammation is only in the front of the eye, there must also be evidence that it is affecting the posterior segment, which is the area at the back of the eye.
Your disease must be active, meaning the inflammation is currently ongoing at the start of the study.
For those in Part A of the study, your Best Corrected Visual Acuity, which is the best vision you can achieve while wearing glasses or contact lenses, must be between 10 and 65 letters on a standardized eye chart.
For those in Part B of the study, your Best Corrected Visual Acuity must be between 10 and 75 letters on a standardized eye chart.

Who Cannot Join the Study?

Your best-corrected visual acuity (the clearest vision you can achieve using glasses or contact lenses) must be better than 30 letters on a standard eye chart (which is similar to seeing 20/250 or worse).
Your intraocular pressure (the fluid pressure inside your eye) must not be lower than 5 mm Hg at the start of the study.
Your intraocular pressure (the fluid pressure inside your eye) must not be higher than 25 mm Hg on the first day of the study, though you may use eye drops to lower this pressure if allowed.
You cannot have infectious uveitis, which is an inflammation of the middle layer of the eye caused by an infection like a virus or bacteria.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Centre Hospitalier Universitaire De Nantes	Nantes	France
Hopital Beaujon	Clichy	France

Trial status

Country	Status	Recruitment Start
France	Not yet recruiting	01.04.2026

Trial locations

REGN7041 is an experimental medicine given by injection into the eye. It is designed to target and block a specific part of the immune system to help reduce inflammation in the back part of the eye.

Investigated diseases:

Uveitis

Noninfectious uveitis – This condition involves inflammation inside the eye that is not caused by an infection. The inflammation can affect different parts of the eye, such as the iris or the middle layer of the eye. It often occurs when the body’s immune system mistakenly attacks healthy eye tissues. As the condition progresses, the inflammation can cause redness, pain, and blurred vision. It may also lead to the formation of small particles in the fluid inside the eye.

Trial ID:

2025-521713-57-00

Protocol code:

R7041-NIU-24123

Trial Phase:

Phase I and Phase II (Integrated) – First administration to humans

Other Trials to Consider

#1 Clinical Trials Search in Europe

A study to evaluate the safety of REGN7041 in adults with active noninfectious uveitis affecting the back of the eye.

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?